ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndromeA high proportion of patients had...
- Marked increases in overall survival observed across soft tissue sarcoma patients - - Demonstrated improvement of median progression free...
Early on-treatment ctDNA reduction in stable disease patients treated with KIMMTRAK was associated with longer overall survival (OXFORDSHIRE, England &...
– Additional data from Phase 1 combination with FOLFIRI continues to show encouraging activity in median third-line metastatic colorectal cancer...
CALGARY, Alberta, June 02, 2023 (GLOBE NEWSWIRE) -- Providence Therapeutics Holdings Inc. ("Providence"), a biopharmaceutical company developing messenger RNA (mRNA)...
HAMPTON, N.J., June 02, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a...
Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of...
BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Folia Health, a health technology company and a leader in patient-centered outcomes research,...
CAMBRIDGE, Mass. and NEW YORK, June 02, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision...
SAN DIEGO, June 02, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on...
Sydney, Australia, June 02, 2023 (GLOBE NEWSWIRE) -- Immutep Limited, an Australian company (ASX: IMM) (Nasdaq: IMMP) (Immutep or the...
New data emphasizes the value of MRD testing in predicting survival outcomes and informing the personalized treatment of patients with...
BNT316/ONC-392 is a next-generation anti-CTLA-4 monoclonal antibody candidate jointly developed by BioNTech and OncoC4 as monotherapy or combination therapy in...
Dr. Wang appointed by the OBI Pharma Board of Directors as Chief Executive Officer to lead OBI Pharma with a...
Brings total Series A funding to over $28 million allowing CyPep-1 to advance into Phase 2 Bergen, Norway, June 2,...
Seer’s Proteograph XT pushes the boundaries of biological discovery by enabling rapid proteomics across a range of sample types and...
LOS ANGELES, June 01, 2023 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) is proud to announce the recipients of...
– YUSIMRY™ (adalimumab-aqvh) will be the first biologic product offered by the Mark Cuban Cost Plus Drug Company – – YUSIMRY will...
Seasoned sector leaders will advise Culture’s leadership in customer intelligence and innovationSAN FRANCISCO, June 01, 2023 (GLOBE NEWSWIRE) -- Culture...
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (or the “Company”) (NASDAQ: AMAM), today announced...